2022
DOI: 10.1177/10732748221076682
|View full text |Cite
|
Sign up to set email alerts
|

Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer

Abstract: Background The FAT atypical cadherin 1/2/3/4 (FAT1/2/3/4) has been linked to the occurrence and development of various cancers. However, the prognostic and immunological role of FAT1/2/3/4 in non-small cell lung cancer (NSCLC) has not been clarified. Methods The association of FAT1/2/3/4 mutations with tumor mutation burden (TMB), tumor immunity in the microenvironment, and response to ICIs in NSCLC was investigated. Whole-exome sequencing data of lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC)… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

4
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(16 citation statements)
references
References 57 publications
(70 reference statements)
4
12
0
Order By: Relevance
“…Interestingly, mutations in these junction proteins show high neoantigen potentials, which is correlated with T-lymphocyte infiltration and better clinical outcomes after immune therapy with immune checkpoint inhibitors (ICIs). Similar immune regulatory effects have also been reported in other studies, namely, that somatic mutations in atypical cadherin proteins, e.g., members of the FAT family, can promote cancer development, while patients with such mutations usually show higher mutation burdens, longer survival times, or better therapeutic outcomes by ICI therapy than patients without [ 116 , 117 , 118 ].…”
Section: Regulation Of Immune Tme By Mutations In Cytoskeleton-associ...supporting
confidence: 77%
“…Interestingly, mutations in these junction proteins show high neoantigen potentials, which is correlated with T-lymphocyte infiltration and better clinical outcomes after immune therapy with immune checkpoint inhibitors (ICIs). Similar immune regulatory effects have also been reported in other studies, namely, that somatic mutations in atypical cadherin proteins, e.g., members of the FAT family, can promote cancer development, while patients with such mutations usually show higher mutation burdens, longer survival times, or better therapeutic outcomes by ICI therapy than patients without [ 116 , 117 , 118 ].…”
Section: Regulation Of Immune Tme By Mutations In Cytoskeleton-associ...supporting
confidence: 77%
“…As shown in Supplementary Figure 4 , FAT mutations significantly prolonged PFS and OS of patients with STAD or uterine corpus endometrial carcinoma and were detrimental to survival in patients with esophageal carcinoma, adrenocortical carcinoma, kidney renal papillary cell carcinoma, pancreatic adenocarcinoma, or pheochromocytoma and paraganglioma, suggesting FAT mutations were related to several tumors and might differentially affect tumor growth by regulating different biological processes. Recently, Feng et al discover that FAT family genes are potential prognostic and immunological biomarkers and correlate with response to ICIs in non-small cell lung cancer ( 50 ), demonstrating that FAT family may also play roles in STAD immunotherapy. Another study reveals NFκB (RelA)/RelA/p65 as the transcriptional regulator of FAT1 gene in GBM cells ( 51 ), suggesting that transcriptional regulators might control the downstream signaling of FAT genes.…”
Section: Discussionmentioning
confidence: 99%
“…In NSCLC cohort treated with ICI, FAT2 mutations may predict better clinical beneficial response and longer progression‐free survival. 17 Based on the above information, we infer that FAT2 may get involved in the tumorigenesis, progression, and treatment of UCEC.…”
Section: Introductionmentioning
confidence: 89%